Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The preliminary results of a clinical safety review that partly used the Cochrane methodology are presented. Despite methodological limitations including incomplete databases, this review collated evidence corroborating the benign safety profile of the artemisinin type of compounds. No difference was apparent amongst the various derivatives. At the time the workshop was held, 188 studies had been identified of which 108 (enrolling 9,241 patients) fulfilled criteria for analyses. These included both uncomplicated and severe malaria patients enrolled in either controlled and non-controlled studies as well as healthy volunteers. Safety was assessed by analysing adverse events, as well as clinical laboratory (haematology assessed in 4,062, blood chemistry in 3,893 patients), electrocardiographic (2638 patients) and neurological assessments as reported in the papers. No serious adverse event or severe significant toxicity was reported. Overall, the most commonly reported adverse experiences were gastro-intestinal. Occasional neutropenia (1.3%), reticulocytopenia (0.6%), elevated liver enzymes (0.9%) were reported. Transient bradycardia and prolonged QT interval were reported in circa 1.1% of patients monitored. A neurological assessment was performed primarily in the severe malaria patients. No difference was apparent with respect to quinine. In addition, four cases of neuropsychiatric adverse events were reported in patients receiving concomitant mefloquine.


Journal article


Medecine tropicale : revue du Corps de sante colonial

Publication Date





50 - 53


St George's Hospital, London, United Kingdom.


Humans, Gastrointestinal Diseases, Bradycardia, Long QT Syndrome, Neutropenia, Sesquiterpenes, Artemisinins, Antimalarials, Drug Monitoring, Adverse Drug Reaction Reporting Systems, Research Design, Databases, Factual